Abstract:Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. Therefore, the need for new therapeutic strategies is still a challenge. Surgery and chemotherapy represent the first-line interventions; nevertheless, the prognosis for metastatic CRC (mCRC) patients remains unacceptable. An important step towards targeted therapy came from the inhibition of the epidermal growth factor receptor (EGFR) pathway, by the anti-EGFR antibody, Cetuximab, or by specific tyrosine kinase inhibitors (TKI). Cetuximab, a mouse-human chimeric monoclonal antibody (mAb), binds to the extracellular domain of EGFR thus impairing EGFR-mediated signaling and reducing cell proliferation. TKI can affect the EGFR biochemical pathway at different steps along the signaling cascade. Apart from Cetuximab, other anti-EGFR mAbs have been developed, such as Panitumumab. Both antibodies have been approved for the treatment of KRAS-NRAS wild type mCRC, alone or in combination with chemotherapy. These antibodies display strong differences in activating the host immune system against CRC, due to their different immunoglobulin isotypes. Although anti-EGFR antibodies are efficient, drug resistance occurs with high frequency. Resistant tumor cell populations can either already be present before therapy or develop later by biochemical adaptations or new genomic mutations in the EGFR pathway. Numerous efforts have been made to improve the efficacy of the anti-EGFR mAbs or to find new agents that are able to block downstream EGFR signaling cascade molecules. Indeed, we examined the importance of analyzing the anti-EGFR antibody-drug conjugates (ADC) developed to overcome resistance and/or stimulate the tumor host's immunity against CRC growth. Also, patient-derived CRC organoid cultures represent a useful and feasible in vitro model to study tumor behavior and therapy response. Organoids can reflect tumor genetic heterogeneity found in the tissue of origin, representing a unique tool for personalized medicine. Thus, CRC-derived organoid cultures are a smart model for studying the tumor microenvironment and for the preclinical assay of anti-EGFR drugs.

Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7

FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2

Abstract 4962: Discovery of Cancer-Specific E3 Ligase Ligands for Targeted Protein Degradation

Mutational order and epistasis determine the consequences of FBXW7 mutations during colorectal cancer evolution

FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression

Fbxw7-associated drug resistance is reversed by induction of terminal differentiation in murine intestinal organoid culture

Molecular insights and clinical implications for the tumor suppressor role of SCFFBXW7 E3 ubiquitin ligase

An FBXW7-ZEB2 Axis Links EMT and Tumour Microenvironment to Promote Colorectal Cancer Stem Cells and Chemoresistance.

FBXW7 in Cancer: What Has Been Unraveled Thus Far?

Perturbation of the Mutated Egfr Interactome Identifies Vulnerabilities and Resistance Mechanisms

The CRISPR/Cas9 System Targeting EGFR Exon 17 Abrogates NF-κB Activation Via Epigenetic Modulation of UBXN1 in EGFRwt/vIII Glioma Cells

Abstract LT10: Recurrent FBXW7 Mutations Bypass Wnt/β-catenin Addiction in Cancer

Identification of Genes Involved in EGF-induced Apoptosis Using CRISPR/Cas9 Knockout Screening: Implications for Novel Therapeutic Targets in EGFR-Overexpressing Cancers

Clinical significance of FBXW7 loss of function in human cancers

Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance

Recurrent mutations in tumor suppressor FBXW7 bypass Wnt/β-catenin addiction in cancer

Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC.

Regulation of BRAF protein stability by a negative feedback loop involving the MEK–ERK pathway but not the FBXW7 tumour suppressor

FBXO32 targets PHPT1 for ubiquitination to regulate the growth of EGFR mutant lung cancer

Abstract 5586: Hijacking mutant E3 ligase for targeted protein degradation: Discovery of cancer-specific PROTACs for the treatment of FBXW7 R465C driven cancers

Cancer Growth Factor Receptor ( EGFR ) Exon 20 Insertion Mutations in Lung Structural , Biochemical , and Clinical Characterization of Epidermal